Literature DB >> 16244776

eNOS gene affects red cell deformability: role of T-786C, G894T, and 4a/4b polymorphisms.

Cinzia Fatini1, Lucia Mannini, Elena Sticchi, Emanuele Cecchi, Alessia Bruschettini, Emanuela Leprini, Paolo Pagnini, Gian Franco Gensini, Domenico Prisco, Rosanna Abbate.   

Abstract

Plasma viscosity and erythrocyte deformability play a key role in maintaining and regulating microcirculation. In vitro and in vivo studies suggested a role for nitric oxide (NO) in modulating flow-mediated vasodilatation and red blood cell deformability. Impaired NO availability due to mutations in eNOS gene might contribute to the altered haemorheologic state. The aim of this study was to investigate the role of eNOS T-786C, G894T, and 4a/4b polymorphisms in modulating the haemorheologic state in a clinical condition characterized by a microcirculatory disorder. Eighty patients with idiopathic sudden sensorineural hearing loss (ISSHL) and 80 healthy subjects were studied. By using a dominant model of inheritance, we found a significant association between eNOS 894T rare variant and ISSHL (odds ratio [OR] 894TT+GT = 2.08, p = 0.03) after adjustment with traditional vascular risk factors. A higher percentage of altered red cell deformability both in patients and in controls carrying the eNOS rare variants was found in comparison to subjects carrying the wild type. Apart from the disease, eNOS T-786C and G894T polymorphisms independently affected the deformability index (OR, -786CC+TC = 2.81, p = 0.01 and OR, 894TT+GT = 2.5, p = 0.02, respectively), in particular in subjects in whom the contemporary presence of the two rare alleles was observed (OR, -786CC+TC and 894TT+GT combined genotype = 6.9, p<0.0001). Our study documented that eNOS gene affects the red blood cell deformability, so possibly contributing to ISSHL, which may represent a suitable model of microcirculatory disorder.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16244776     DOI: 10.1177/107602960501100417

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  2 in total

1.  Randomized trial of inhaled nitric oxide to treat acute pulmonary embolism: The iNOPE trial.

Authors:  Jeffrey A Kline; Cassandra L Hall; Alan E Jones; Michael A Puskarich; Ronald A Mastouri; Tim Lahm
Journal:  Am Heart J       Date:  2017-01-27       Impact factor: 4.749

2.  eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity.

Authors:  S Nagassaki; R D Herculano; C F O Graeff; J E Tanus-Santos
Journal:  Eur J Clin Pharmacol       Date:  2008-12-23       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.